XIV Eurasian Hematology-Oncology Congress - EHOC 2023

 

XIV Eurasian Hematology-Oncology Congress - EHOC 2023
E

IKEMA Trial Final Updates: Carfilzomib/Dex +/- Isatuximab in Patients With R/R MM

By XIV Eurasian Hematology-Oncology Congress - EHOC 2023 FEATURING Ecenur Güder Arslan
By XIV Eurasian Hematology-Oncology Congress - EHOC 2023 FEATURING Ecenur Güder Arslan
14 views
February 15, 2024
0 Comments
Login to view comments. Click here to Login
Myeloma
10:39
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Real-World Treatment Patterns and Outcomes in Patients With R/R MM W…

Feat. Ö. Pektaş
08:04
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Future Perspectives on the Management of Myeloma: Cure or Longterm D…

Feat. R. Magalhaes
10:04
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Debates in Myeloma: Smoldering Myeloma Should NOT Be Treated

Feat. E. Terpos
09:46
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Debates in Myeloma: Smoldering Myeloma Should Be Treated

Feat. C. Cerchione
21:44
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

How I Manage Late Relapsed Myeloma With T-Cell Engaging Therapy

Feat. A. Romano
07:42
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Case Presentation: R/R Myeloma With Extramedullary Plasmacytoma Invo…

Feat. A. Yeşilaltay
13:54
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

MRD in the Era of Modern MM Therapies

Feat. R. Magalhaes
24:29
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

How I Treat R/R MM With CAR-T and Bispecific Antibodies

Feat. C. Cerchione
07:23
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

IKEMA Trial Final Updates: Carfilzomib/Dex +/- Isatuximab in Patient…

Feat. E. Güder Arslan